LEXG-Lexicon Genetics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics

LXRX 1.390

+3.7%

Oct 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (133)	1/8/2003 10:14:43 AM
From: nigel bates	of 254

THE WOODLANDS, Texas, Jan. 8 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that it has extended its OmniBank® Universal agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD). Under the terms of the agreement, J&JPRD will continue its access to Lexicon's OmniBank library through December 2003. J&JPRD will also continue to have access to gene knockouts generated under Lexicon's patented gene targeting technologies with genetic alterations directed at specific drug targets of interest, and access to drug target validation data generated by Lexicon for specified targets. Financial terms of the arrangement were not disclosed...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next